K. Sexton

发表

Primary breast cancer phenotypes associated with propensity for central nervous system metastases

S. Hilsenbeck, R. Elledge, Y. Tham, 2006, Cancer.

BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer.

A. Makris, C. Osborne, A. Pavlick, 2009 .

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency

S. Hilsenbeck, W. Woodward, C. Creighton, 2013, Breast Cancer Research.

Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer

John Quackenbush, Carolina Gutierrez, John Quackenbush, 2009, Clinical Cancer Research.

Human Cancer Biology Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor – Negative Breast Cancer

John Quackenbush, S. Hilsenbeck, P. Brown, 2009 .

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

S. Hilsenbeck, S. Fuqua, R. Elledge, 2011, Breast Cancer Research and Treatment.

A review of body size and breast cancer risk in Hispanic and African American women

S. Vernon, M. Bondy, R. S. Day, 2011, Cancer.

Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.

S. Hilsenbeck, C. Osborne, P. Brown, 2009, Journal of the National Cancer Institute.

The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Followed by a Taxane

R. Elledge, H. Weiss, Y. Tham, 2007, American journal of clinical oncology.

The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.

R. Elledge, H. Weiss, Y. Tham, 2006, The journal of supportive oncology.

Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers

S. Hilsenbeck, P. Brown, N. Sneige, 2008 .